Trial Profile

Phase II Clinical Study of the Combination of Apatinib and PD1 in Treating Advanced Gastric Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Irinotecan (Primary) ; Programmed cellular immunotherapeutic (Primary) ; Rivoceranib (Primary)
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Therapeutic Use

Most Recent Events

22 Jan 2022 Status changed to completed, according to Results presented at the 2022 Gastrointestinal Cancers Symposium.
22 Jan 2022 Results presented at the 2022 Gastrointestinal Cancers Symposium.
04 Jun 2021 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified May 2019).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com